Coronary artery disease involving the left anterior descending (LAD) artery remains one of the most clinically significant forms of ischemic heart disease. Because the LAD supplies a large portion of the left ventricular myocardium, optimal revascularization strategies are essential to improve survival and reduce symptoms. Traditionally, treatment options include percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or surgical revascularization using coronary artery bypass grafting (CABG). In recent years, minimally invasive direct coronary artery bypass (MIDCAB) has emerged as a less invasive surgical alternative to conventional CABG, avoiding sternotomy and cardiopulmonary bypass while still utilizing the durable left internal thoracic artery (LITA) graft to the LAD.
This study examined the long-term outcomes of patients who underwent LAD revascularization using either MIDCAB or PCI with drug-eluting stents. The investigation was conducted as a retrospective two-center study involving patients treated between May 2002 and December 2003. Researchers initially reviewed 376 patients with coronary artery disease. Of these, 272 underwent PCI with a Cypher drug-eluting stent and 104 underwent MIDCAB surgery using a LITA-to-LAD graft. For a balanced comparison, the investigators matched patients based on age, sex, and extent of coronary artery disease, producing two comparable groups of 83 patients each.Â
Early outcomes between the two procedures were generally favorable. Thirty-day mortality was low in both groups, with a rate of 1.1% following MIDCAB and 0% following DES-PCI. These findings highlight that both revascularization strategies are relatively safe when performed in experienced centers. However, differences became more apparent when examining symptomatic outcomes and the need for repeat interventions.
At the two-year follow-up, patients who underwent MIDCAB experienced significantly fewer episodes of recurrent angina compared with those who received drug-eluting stents. Only 8.4% of MIDCAB patients reported recurrent angina compared with 35% of patients in the DES group. Additionally, repeat revascularization procedures were considerably less common in the surgical cohort, occurring in 3.6% of MIDCAB patients versus 16.8% of those treated with PCI. These findings suggest that surgical grafting with the internal thoracic artery may provide more durable relief from ischemic symptoms in isolated LAD disease.
Major adverse cardiac events (MACE), including cardiac death, myocardial infarction, or repeat intervention, also differed between the two approaches in early follow-up. The DES group experienced higher MACE rates compared with MIDCAB patients. Statistical analysis demonstrated that treatment with drug-eluting stents was an independent predictor of recurrent angina and reintervention during the first two years after treatment. These results reinforce prior evidence suggesting that internal thoracic artery grafts to the LAD offer excellent long-term patency and durable clinical outcomes.
A unique strength of this study is its extended follow-up period. Researchers reexamined the cohort nearly two decades later using national registry data to evaluate long-term survival. The mean follow-up duration was approximately 16 years, with survival analysis extending up to 20 years.
Long-term survival results were remarkably similar between the two treatment groups. Ten-year survival rates were 77.1% for patients undergoing MIDCAB and 81.0% for those treated with DES-PCI. At 20 years, survival remained comparable, with rates of approximately 60.2% for the MIDCAB group and 56.1% for the DES group. Statistical analysis confirmed that these differences were not significant.Â
Multivariable regression analysis identified several predictors of long-term mortality. Advanced age and prior myocardial infarction were independently associated with increased risk of death. Interestingly, treatment with MIDCAB demonstrated a trend toward improved long-term survival compared with DES, although the result narrowly missed statistical significance.
The authors also discussed the evolving role of MIDCAB in contemporary cardiac surgery. The procedure is performed through a small anterolateral thoracotomy and allows surgeons to graft the LITA to the LAD on a beating heart without cardiopulmonary bypass. This minimally invasive approach reduces surgical trauma while preserving the durability of arterial bypass grafting. Over the past two decades, the technique has expanded further with robotic and thoracoscopic assistance.
Despite the promising findings, several limitations should be considered when interpreting the results. The study design was retrospective and nonrandomized, introducing potential selection bias. Treatment allocation depended on clinical judgment and anatomical suitability rather than random assignment. In addition, the PCI procedures used first-generation drug-eluting stents, which differ from the newer stent technologies used in modern practice. As a result, outcomes for contemporary PCI may differ from those observed in this historical cohort.
Another limitation is the lack of detailed long-term data regarding cardiac-specific events such as myocardial infarction or repeat interventions beyond the early follow-up period. The extended analysis focused primarily on overall survival rather than comprehensive clinical outcomes.
Overall, this study provides valuable insight into long-term outcomes of LAD revascularization strategies. The findings demonstrate that both MIDCAB surgery and PCI with drug-eluting stents provide excellent long-term survival. However, MIDCAB appears to offer superior early symptomatic relief and lower rates of repeat revascularization. These results support the continued role of minimally invasive surgical bypass as an effective and durable treatment option for patients with isolated LAD disease, particularly when anatomical features make PCI less favorable.
